{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:48:43Z","timestamp":1787662123282,"version":"build-2736575974"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007292","name":"Nurses Organization of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007292","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.atherosclerosis.2026.120682","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:11:45Z","timestamp":1771027905000},"page":"120682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["In silico prediction of the lipid-lowering efficacy of the oral PCSK9 inhibitor enlicitide using a mechanistic computational model"],"prefix":"10.1016","volume":"415","author":[{"given":"Bertrand","family":"Cariou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yishu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Angoulvant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Boccara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Mah\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5528-0263","authenticated-orcid":false,"given":"Emmanuelle","family":"Bechet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2026.120682_bib1","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg Heal - Eur"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2026.120682_bib2","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1002\/psp4.13208","article-title":"Landscape of regulatory quantitative systems pharmacology submissions to the U.S. food and drug administration: an update report","volume":"13","author":"Bai","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2026.120682_bib3","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/psp4.12669","article-title":"Scientific and regulatory evaluation of mechanistic in silico drug and disease models in drug development: building model credibility","volume":"10","author":"Musuamba","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.120682_bib4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41746-025-01557-7","article-title":"Credibility assessment of a mechanistic model of atherosclerosis to predict cardiovascular outcomes under lipid-lowering therapy","volume":"8","author":"Wang","year":"2025","journal-title":"npj Digit Med"},{"issue":"15","key":"10.1016\/j.atherosclerosis.2026.120682_bib5","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1093\/eurjpc\/zwae254","article-title":"In-silico trial emulation to predict the cardiovascular protection of new lipid-lowering drugs: an illustration through the design of the SIRIUS programme","volume":"31","author":"Angoulvant","year":"2024","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2026.120682_bib6","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1161\/CIRCULATIONAHA.122.063372","article-title":"Orally bioavailable macrocyclic peptide that inhibits binding of PCSK9 to the low density lipoprotein receptor","volume":"148","author":"Johns","year":"2023","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.atherosclerosis.2026.120682_bib7","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jacc.2023.02.018","article-title":"Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616","volume":"81","author":"Ballantyne","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2026.120682_bib8","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated Statin therapy","volume":"27","author":"Ballantyne","year":"2020","journal-title":"Eur J Prev Cardiol"},{"issue":"18","key":"10.1016\/j.atherosclerosis.2026.120682_bib9","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120682_bib10","article-title":"Prospective prediction of LDL-C outcomes for CORALreef AddOn and CORALreef lipids using a mechanistic QSP model of ASCVD (v1.0)","author":"Monteiro","year":"2025","journal-title":"Zenodo"},{"key":"10.1016\/j.atherosclerosis.2026.120682_bib11","series-title":"Merck. Merck's enlicitide decanoate, an investigational oral PCSK9 inhibitor, significantly reduced LDL-C in phase 3 CORALreef lipids trial","year":"2025"},{"key":"10.1016\/j.atherosclerosis.2026.120682_bib12","article-title":"Oral PCSK9 inhibitor enlicitide cuts LDL cholesterol: CORALreef lipids","author":"O'Riordan","year":"2025","journal-title":"TCTMD"},{"key":"10.1016\/j.atherosclerosis.2026.120682_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwaf783","article-title":"Prediction of inclisiran efficacy in patients with established atherosclerotic cardiovascular disease: the SIRIUS in-silico modelling of cardiovascular outcomes","author":"Angoulvant","year":"2025","journal-title":"Eur J Prev Cardiol"},{"issue":"16_suppl","key":"10.1016\/j.atherosclerosis.2026.120682_bib14","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.8614","article-title":"Prospective validation of in silico clinical trials prediction using an EGFR-mutated NSCLC mechanistic computational disease model","volume":"42","author":"Duruisseaux","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026000481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026000481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:36:20Z","timestamp":1779251780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915026000481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":14,"alternative-id":["S0021915026000481"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.120682","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In silico prediction of the lipid-lowering efficacy of the oral PCSK9 inhibitor enlicitide using a mechanistic computational model","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.120682","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120682"}}